Industry news
- Industry news
- Regulatory
- News
EISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE
In order to access this content you must be logged in and have a subscription to Pharmalicensing Intelligence.
Pharmalicensing Intelligence is a one-stop environment for time-conscious executives. Keeping you abreast of the latest developments in the life sciences industry, saving you time and money when you need it most.
Company details
If you want to find out more about the company visit Eisai profile.
Related reports
Related news
Latest News
- Straumann launches new CADCAM dental restoration system
- Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
- Quidel Announces FDA Clearance of Its RapidVue(R) hCG Pregnancy Lateral Flow Diagnostic Test
- Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients
- GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
- EISAI ANNOUNCES EXTENSION OF FDA REVIEW OF DRUG APPLICATION FOR INVESTIGATIONAL AGENT ERIBULIN MESYLATE
- Roche provides update on FDA application for T-DM1
- Genentech Provides Update on FDA Application for T-DM1
- YM BioSciences granted Orphan Drug Designation for CYT387
- YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
- More news... | RSS Feed...
Most Viewed
Straumann launches new CADCAM dental restoration system
Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
Quidel Announces FDA Clearance of Its RapidVue(R) hCG Pregnancy Lateral Flow Diagnostic Test
YM BioSciences granted Orphan Drug Designation for CYT387
The Gamida Cell-TEVA Joint Venture Receives FDA Fast Track Designation for StemEx
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us